AlphaMark Advisors LLC increased its holdings in Mylan NV (NASDAQ:MYL) by 1.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 107,329 shares of the company’s stock after acquiring an additional 2,025 shares during the quarter. Mylan makes up about 1.6% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 19th largest position. AlphaMark Advisors LLC’s holdings in Mylan were worth $3,928,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the stock. James Investment Research Inc. lifted its stake in Mylan by 9.5% in the second quarter. James Investment Research Inc. now owns 16,915 shares of the company’s stock worth $611,000 after acquiring an additional 1,470 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in Mylan by 0.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 218,314 shares of the company’s stock worth $7,990,000 after acquiring an additional 1,603 shares during the period. Sumitomo Life Insurance Co. lifted its stake in Mylan by 4.1% in the second quarter. Sumitomo Life Insurance Co. now owns 42,775 shares of the company’s stock worth $1,546,000 after acquiring an additional 1,679 shares during the period. Alerus Financial NA lifted its stake in Mylan by 1.6% in the second quarter. Alerus Financial NA now owns 111,011 shares of the company’s stock worth $4,011,000 after acquiring an additional 1,697 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Mylan by 8.5% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 21,998 shares of the company’s stock worth $794,000 after acquiring an additional 1,726 shares during the period. 82.99% of the stock is owned by institutional investors.
Shares of Mylan stock opened at $36.43 on Wednesday. The stock has a market capitalization of $16.33 billion, a price-to-earnings ratio of 7.99, a PEG ratio of 1.02 and a beta of 1.53. The company has a quick ratio of 0.77, a current ratio of 1.29 and a debt-to-equity ratio of 1.18. Mylan NV has a one year low of $30.33 and a one year high of $47.82.
Mylan (NASDAQ:MYL) last announced its earnings results on Monday, November 5th. The company reported $1.25 EPS for the quarter, topping the Zacks’ consensus estimate of $1.19 by $0.06. The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.91 billion. Mylan had a net margin of 3.90% and a return on equity of 18.48%. The firm’s revenue was down 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.10 earnings per share. On average, sell-side analysts anticipate that Mylan NV will post 4.62 EPS for the current year.
MYL has been the subject of a number of research reports. Cowen reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Mylan in a research note on Thursday, August 9th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Mylan in a research note on Wednesday, July 25th. ValuEngine raised shares of Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Royal Bank of Canada set a $50.00 target price on shares of Mylan and gave the stock a “buy” rating in a report on Tuesday. Finally, Mizuho downgraded shares of Mylan from a “buy” rating to a “neutral” rating in a report on Friday, October 5th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. Mylan has an average rating of “Buy” and an average price target of $47.40.
ILLEGAL ACTIVITY WARNING: “AlphaMark Advisors LLC Grows Position in Mylan NV (MYL)” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://theenterpriseleader.com/2018/11/07/alphamark-advisors-llc-grows-position-in-mylan-nv-myl.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Further Reading: Diversification in Investing
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.